Jatenzo Cost in Indiana 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is Jatenzo and Why Does It Cost So Much?

Jatenzo is the first FDA-approved oral testosterone replacement therapy in the United States, cleared in March 2019 under NDA 210134 for adult males with conditions associated with a deficiency or absence of endogenous testosterone [1]. It uses a self-emulsifying drug delivery system that routes testosterone undecanoate through intestinal lymphatic absorption, bypassing first-pass hepatic metabolism. That proprietary delivery technology is a large part of why the drug commands a premium price compared with generic injectable testosterone.

The key registration study, Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166), found that 87% of patients achieved average total testosterone concentrations within the normal eugonadal range (300 to 1 to 000 ng/dL) at steady state when taking Jatenzo twice daily with food [2]. Mean Cavg across the trial was 489 ng/dL. Those efficacy results supported FDA approval, but the drug has never faced generic competition and Tolmar Pharmaceuticals sets the wholesale acquisition cost accordingly.

At Indiana retail pharmacies in 2026, the cash price for a 30-day supply sits at approximately $900, consistent with the national average [3]. GoodRx and similar coupon platforms rarely discount Jatenzo below $800 at Indiana chains such as CVS, Walgreens, or Kroger because no generic exists and the drug does not participate in most discount formularies. Patients without commercial insurance coverage face the full freight unless they qualify for manufacturer assistance.

The FDA label for Jatenzo carries a boxed warning about blood pressure elevation [1]. In the Swerdloff trial, mean systolic BP rose by 3 to 5 mmHg from baseline [2]. Prescribers in Indiana must document BP at baseline and monitor it during therapy, which adds office-visit cost to the overall treatment budget.

Indiana Medicaid Coverage for Jatenzo in 2026

Indiana Medicaid does not cover Jatenzo for male hypogonadism. This is a firm exclusion, not simply a prior-authorization hurdle.

The Indiana Family and Social Services Administration (FSSA) Medicaid drug program applies a medical necessity framework that restricts brand testosterone products with no generic equivalent when lower-cost alternatives exist [4]. Injectable testosterone cypionate and testosterone enanthate, both available as generics at under $30 per month, satisfy the same clinical indication and are covered. Because Jatenzo offers no clinical advantage over injectables sufficient to justify its price under Indiana's cost-effectiveness threshold, the state's Preferred Drug List (PDL) excludes it for hypogonadism.

One narrow pathway does exist. Indiana Medicaid may approve Jatenzo for patients who also carry a diagnosis of type 2 diabetes where hypogonadism is documented as a complicating factor, consistent with data linking low testosterone to insulin resistance [5]. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states that "testosterone therapy in men with hypogonadism and type 2 diabetes may improve glycemic control and insulin sensitivity" [6]. An Indiana Medicaid prior-authorization request citing that comorbidity and supported by an endocrinologist letter has the best chance of approval. Success rates remain low, but the route is not categorically closed.

Patients on Hoosier Care Connect or other managed Medicaid plans should contact their plan's pharmacy benefit manager directly. Each MCO administers its own PDL exceptions process, and documentation requirements differ.

Private Insurance and Employer Plans in Indiana

Commercial insurance coverage for Jatenzo in Indiana spans a wide range, from full coverage at a specialty-tier copay to outright exclusion.

Large self-insured employers in Indiana, including many manufacturing firms, sometimes carry broad specialty formularies that include Jatenzo after prior authorization. A typical PA requires documentation of two serum total testosterone measurements below 300 ng/dL drawn before 10 a.m., a diagnosis code consistent with primary or secondary hypogonadism, and confirmation that the patient has tried or is contraindicated to generic alternatives [7]. The American Urological Association's 2018 guideline on testosterone deficiency recommends measuring total testosterone twice before initiating therapy, which aligns directly with most insurer PA criteria [8].

ACA marketplace plans sold through the Indiana exchange vary considerably. Silver-tier plans from Anthem and MDwise have historically placed Jatenzo on specialty tier 4 or 5, generating monthly copays between $150 and $400 after deductible. Some Blue Cross Blue Shield of Indiana individual plans exclude it entirely. Patients should request a formulary exception in writing and attach the prescribing physician's letter of medical necessity.

Medicare Part D coverage depends on the specific plan. CMS does not classify testosterone products as a protected class drug category, so Part D plans are not required to cover them. As of 2026, fewer than 30% of Indiana Part D plans include Jatenzo on any tier [4]. Patients enrolled in Medicare Advantage should check the Evidence of Coverage document for their specific plan.

The Tolmar Savings Card: How It Works in Indiana

Tolmar offers a manufacturer copay savings card for Jatenzo that can reduce out-of-pocket cost to $0 per month for eligible commercially insured patients in Indiana.

The program works as a secondary payer. After the patient's commercial insurance processes the claim, the savings card pays the remaining balance up to a defined annual cap. As of 2026, the cap sits at $6,000 per calendar year, meaning the card absorbs up to $500 per month in residual cost. Patients activate the card at jatenzo.com and present it at the pharmacy alongside their insurance card [9].

Critical eligibility restrictions apply. The savings card is not valid for patients covered by any government-funded program, including Indiana Medicaid, Medicare Part D, Medicaid managed care, TRICARE, or the VA. Indiana residents who are self-pay (no insurance at all) also do not qualify, because the card requires a primary insurance claim to process. Those patients must seek alternative cost reduction through the Tolmar patient assistance program (PAP), which provides free drug to uninsured or underinsured patients who meet income thresholds, generally at or below 400% of the federal poverty level.

To apply for the PAP, Indiana patients call Tolmar Medical Affairs at 1-855-855-2273 and submit proof of income and a signed prescriber attestation. Processing takes 10 to 15 business days. Bridge supply of up to 30 days is sometimes available while the application is reviewed.

Compounded Oral Testosterone Undecanoate in Indiana: Legality and Cost

Licensed 503A compounding pharmacies in Indiana may legally prepare oral testosterone undecanoate capsules for individual patients with a valid prescription.

Testosterone is a Schedule III controlled substance under the Controlled Substances Act, which means compounding pharmacies must hold a DEA registration to handle it. Indiana does not impose additional state-level restrictions on compounding Schedule III testosterone beyond federal requirements, provided the pharmacy operates under a valid Indiana Board of Pharmacy license and compounds only pursuant to a patient-specific prescription from a licensed prescriber [10].

The legal basis for this rests on Section 503A of the Federal Food, Drug, and Cosmetic Act, which exempts patient-specific compounded preparations from the FDA's new drug approval process when prepared by a licensed pharmacist for an identified patient based on a valid prescription. Bulk testosterone undecanoate is available to licensed compounders from FDA-registered active pharmaceutical ingredient suppliers.

Cost is the decisive advantage. Indiana compounding pharmacies that prepare oral testosterone undecanoate typically charge between $40 and $120 per month, depending on dose and capsule count. That represents a savings of $780 to $860 per month relative to brand Jatenzo at list price.

The clinical trade-off deserves direct explanation. Compounded testosterone undecanoate formulations may not replicate the precise self-emulsifying delivery system patented by Tolmar. Bioavailability could differ from the brand product studied in Swerdloff et al. [2]. Prescribers monitoring compounded therapy should still target morning total testosterone between 300 and 1 to 000 ng/dL, check BP at each visit, and use the same hematocrit and PSA monitoring schedule recommended in the Endocrine Society guideline [6]. Patients switching from brand Jatenzo to a compounded formulation need a re-titration period with labs at 4 and 8 weeks.

The FDA's 2020 guidance on compounding from bulk drug substances clarifies that testosterone undecanoate is not on the 503A Bulks List that would restrict its use, meaning it remains available to 503A compounders [11]. Indiana pharmacists should confirm their specific supplier's API registration status annually.

Telehealth Prescribing of Jatenzo in Indiana

Indiana law permits telehealth prescribing of Jatenzo by licensed Indiana or out-of-state prescribers who comply with Indiana's telehealth statute (IC 25-1-9.5).

As of January 2025, Indiana allows controlled substance prescribing via telehealth for Schedule III drugs without a prior in-person visit, provided the prescriber uses a two-way, real-time audio-video platform and documents a clinical evaluation sufficient to establish the diagnosis [12]. Testosterone undecanoate as a Schedule III substance qualifies under this framework.

A telehealth visit for hypogonadism in Indiana requires the prescriber to review labs (two morning total testosterone values below 300 ng/dL), confirm symptoms consistent with testosterone deficiency (reduced libido, fatigue, loss of muscle mass, depressed mood), and rule out contraindications including prostate cancer, breast cancer, polycythemia, and uncontrolled heart failure. The Endocrine Society guideline specifies that clinicians "should measure testosterone levels in men who present with signs and symptoms of testosterone deficiency" before initiating therapy [6].

Indiana-based telehealth platforms and national platforms licensed in Indiana (such as HealthRX) can prescribe Jatenzo and transmit the prescription electronically to any Indiana pharmacy registered to dispense Schedule III controlled substances. The pharmacy confirms the prescriber's Indiana DEA registration before dispensing. Many telehealth visits for TRT in Indiana complete initial labs through a local draw center (Quest, LabCorp, or hospital outpatient), with results reviewed during the video consultation.

Follow-up monitoring by telehealth is equally legal. Blood pressure readings self-reported by a validated home monitor may satisfy the monitoring requirement between formal in-office BP checks, though prescribers retain discretion on how frequently to verify BP in a clinical setting.

Practical Cost Comparison: All Options for Indiana Patients in 2026

The table below summarizes the realistic monthly cost scenarios an Indiana patient faces in 2026.

Brand Jatenzo, no insurance or savings card: Approximately $900/month at Indiana retail pharmacies [3].

Brand Jatenzo, commercial insurance with PA approved, specialty tier copay: $150 to $400/month after deductible, depending on plan design.

Brand Jatenzo, commercial insurance plus Tolmar savings card: $0/month up to the $6,000 annual cap ($500/month card maximum), meaning effectively $0 for most patients whose insurer covers the bulk of the cost.

Brand Jatenzo, Tolmar PAP (uninsured, income-qualified): $0/month while enrolled.

Compounded oral testosterone undecanoate, 503A Indiana pharmacy: $40 to $120/month, self-pay, no insurance needed.

Generic injectable testosterone cypionate, Indiana pharmacy: Under $30/month, widely covered by Medicaid and most insurance plans. Same Schedule III controlled substance, different route of administration.

For context on how meaningful testosterone treatment can be: hypogonadal men treated with testosterone therapy show improvements in lean body mass, bone mineral density, and sexual function compared with placebo, as demonstrated across multiple randomized trials summarized in the 2018 Endocrine Society guideline [6]. A 2020 meta-analysis published in The Journal of Clinical Endocrinology and Metabolism found that testosterone therapy in men with hypogonadism reduced fat mass by a mean of 1.6 kg and increased lean mass by 1.9 kg over 12 months [13]. The route of delivery, whether oral, injectable, transdermal, or compounded oral, does not change the core clinical goal of restoring serum testosterone to the eugonadal range.

Monitoring Costs Indiana Patients Should Budget For

Beyond the drug cost itself, Indiana patients taking Jatenzo or compounded oral testosterone undecanoate should budget for ongoing laboratory and clinical monitoring.

The FDA label mandates hematocrit monitoring at baseline, at 3 to 6 months after initiating therapy, and annually thereafter [1]. If hematocrit exceeds 54%, the drug must be stopped until levels normalize. Quest Diagnostics and LabCorp both operate collection sites across Indiana, with testosterone panels running $40 to $90 on cash pay and significantly less through insurance.

PSA monitoring is recommended for men over age 40 at baseline and at 3 to 6 months, consistent with the American Urological Association 2018 guideline [8]. Bone mineral density assessment by DXA scan is advisable at baseline for men with a history of osteoporosis or fragility fracture, per the National Osteoporosis Foundation guideline [14].

Blood pressure is the most frequently monitored parameter. The Swerdloff trial reported a mean systolic increase of approximately 4 mmHg, and the FDA required a boxed warning for this reason [1, 2]. Indiana patients using home monitors should log readings weekly for the first 3 months and report any sustained elevation above 130/80 mmHg to their prescriber, consistent with the American Heart Association's 2017 hypertension guideline threshold [15].

A full annual monitoring budget for an Indiana patient on Jatenzo, including two testosterone panels, one complete blood count, one PSA, one basic metabolic panel, and four BP checks, reasonably runs $200 to $400 per year on cash pay or $50 to $150 with commercial insurance.

How to Get the Lowest Legal Price for Jatenzo in Indiana

Follow this sequence to minimize your out-of-pocket cost in Indiana.

First, verify your insurance formulary. Call the member services number on your insurance card and ask specifically whether Jatenzo (NDC prefix 70727) is covered and on which tier. Ask whether a formulary exception process is available and what documentation is required.

Second, if covered, request prior authorization. Your prescriber's office submits the PA with two morning testosterone values, a diagnosis code (ICD-10 E29.1 for testicular hypofunction or E23.0 for hypopituitarism), and a letter of medical necessity. Most Indiana insurers adjudicate PA requests within 3 to 7 business days.

Third, apply for the Tolmar savings card at jatenzo.com before filling your first prescription. The card activates immediately online and the pharmacy applies it at the point of sale alongside your insurance.

Fourth, if uninsured or the savings card does not apply, contact Tolmar's PAP at 1-855-855-2273 to determine income eligibility and begin the application.

Fifth, if cost remains prohibitive, ask your prescriber whether a licensed 503A Indiana compounding pharmacy is an appropriate option for your clinical situation. Confirm the pharmacy holds a current Indiana Board of Pharmacy license and a DEA Schedule III registration. Request a certificate of analysis for the compounded formulation to verify API potency and capsule uniformity before starting.

Sixth, if oral delivery is not a clinical requirement, ask your prescriber whether generic testosterone cypionate 200 mg/mL self-injected weekly or biweekly meets your needs. At under $30 per month and broadly covered by Indiana Medicaid and most private plans, it remains the most cost-effective testosterone replacement option in the state [4].

The Endocrine Society's clinical guideline states: "We suggest that clinicians choose a preparation based on the patient's preference, pharmacokinetics, treatment burden, and cost" [6]. That language gives prescribers and patients in Indiana genuine flexibility to select the most affordable route without compromising clinical standards.